Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald P Radich

Showing results (111-120 of 208) with videos related to

Pageof 21
Sort By:
Blood|October 26, 2006
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaVivian G Oehler, Ted Gooley, David S Snyder, et al.
BMC Cancer|April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaAndrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinibSusan Branford, Dong-Wook Kim, Simona Soverini, et al.
Leukemia & Lymphoma|October 23, 2002
Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantationUwe Platzbecker, Ted Gooley, Claudio Anasetti, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantationOlga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
Leukemia|January 23, 2026
Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncologyVivian G Oehler, Olga Sala-Torra, Neta Gilderman, et al.
Blood|July 13, 2013
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionRoland B Walter, Sarah A Buckley, John M Pagel, et al.
Leukemia|October 4, 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemiaNicholas C P Cross, Thomas Ernst, Susan Branford, et al.
Blood|March 24, 2009
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Todd A Alonzo, Robert B Gerbing, et al.
Pageof 21

Showing results (111-120 of 208) with videos related to

Sort By:
Pageof 21
Blood|October 26, 2006
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaVivian G Oehler, Ted Gooley, David S Snyder, et al.
BMC Cancer|April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaAndrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinibSusan Branford, Dong-Wook Kim, Simona Soverini, et al.
Leukemia & Lymphoma|October 23, 2002
Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantationUwe Platzbecker, Ted Gooley, Claudio Anasetti, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 26, 2006
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantationOlga Sala-Torra, Colleen Hanna, Michael R Loken, et al.
Leukemia|January 23, 2026
Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncologyVivian G Oehler, Olga Sala-Torra, Neta Gilderman, et al.
Blood|July 13, 2013
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionRoland B Walter, Sarah A Buckley, John M Pagel, et al.
Leukemia|October 4, 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemiaNicholas C P Cross, Thomas Ernst, Susan Branford, et al.
Blood|March 24, 2009
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPhoenix A Ho, Todd A Alonzo, Robert B Gerbing, et al.
Pageof 21